{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-sclerosis/diagnosis/confirming-the-diagnosis/","result":{"pageContext":{"chapter":{"id":"fd10e131-3f32-5228-a05b-5a6267fef1b2","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis","depth":2,"htmlHeader":"<!-- begin field 2ef5b7a0-005f-4876-9021-a79b009de741 --><h2>How should I confirm a diagnosis of multiple sclerosis?</h2><!-- end field 2ef5b7a0-005f-4876-9021-a79b009de741 -->","summary":"","htmlStringContent":"<!-- begin item b86f7ab8-0a5d-48ce-aceb-a79b009de397 --><!-- begin field 2f9a6d90-ed8c-43a2-be84-a79b009de741 --><ul><li><strong>If a person has <a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/diagnosis/initial-presentation/\">symptoms and signs</a> suggestive of multiple sclerosis (MS):</strong><ul><li>Refer promptly to a consultant neurologist — early diagnosis and treatment may improve prognosis.</li><li>Only a consultant neurologist should make a diagnosis of MS.</li><li>Speak to a specialist directly if you think the person needs to be seen urgently, for example they present with sudden onset visual loss (to exclude <a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/diagnosis/differential-diagnosis/\">neuromyelitis optica</a>).</li></ul></li><li><strong>Arrange blood tests to help exclude alternative diagnoses, including:</strong><ul><li>Full blood count.</li><li>Inflammatory markers, for example, erythrocyte sedimentation rate or C-reactive protein.</li><li>Liver function tests.</li><li>Renal function tests.</li><li>Calcium.</li><li>Glucose/HbA1c.</li><li>Thyroid function tests.</li><li>Vitamin B12.</li><li>HIV serology.</li></ul></li><li><strong>Urgent referral should not be delayed while awaiting results of blood tests.</strong></li><li><strong>Depending on the clinical presentation, other tests might be appropriate.</strong></li></ul><!-- end field 2f9a6d90-ed8c-43a2-be84-a79b009de741 --><!-- end item b86f7ab8-0a5d-48ce-aceb-a79b009de397 -->","topic":{"id":"d4f5f727-ed37-55a1-abb1-280e5fc9851e","topicId":"5d674db8-174e-4008-be2b-97980377bc61","topicName":"Multiple sclerosis","slug":"multiple-sclerosis","lastRevised":"Last revised in August 2020","chapters":[{"id":"5bcd2220-ea7d-5aa0-b179-870dd52d1a9d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b281488-c1a9-571c-9f76-76a0ca4f3f61","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0268dff6-e6a3-5331-9e13-7258fdfe9bdb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ac99d001-df07-5809-9d43-3d52702e71a7","slug":"changes","fullItemName":"Changes"},{"id":"0c03fe4d-4002-5f0b-a40a-ea4925270b27","slug":"update","fullItemName":"Update"}]},{"id":"6ed54162-5487-59f3-b908-b856fb8f2150","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"952c02eb-45ac-5b32-afcc-183466bb602e","slug":"goals","fullItemName":"Goals"},{"id":"4b841ec7-26b6-5463-a184-0cdf46d3b8a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6282c221-3df8-5a37-a525-cfaf733f007d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c0d0509-a813-56b1-b980-801b252d4045","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bba30032-e86d-577c-a3ca-fa9aed61784a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4744d85-2f18-554f-b380-d3bf10688018","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6c6f57ef-4211-5735-8895-4fda97d92881","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a50c93d9-2521-5417-ad53-bfb7f36d89f3","slug":"definition","fullItemName":"Definition"},{"id":"e8237fd3-792a-578e-b846-57b7431a7db8","slug":"causes","fullItemName":"Causes"},{"id":"0b182587-5c21-57f2-8398-ab8e98fcf8f6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"38108bcd-8a87-5c0b-9ae8-b9db74f1c69a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"37fb0c7f-1f18-5f13-889a-245cc60a3bee","slug":"complications","fullItemName":"Complications"},{"id":"fd2cae1b-67e8-5a36-924e-cda5c20f8a6c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7d30fb43-cd66-5aab-af72-8e461bc91727","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff701475-207f-5854-8697-487b8a3dc212","slug":"initial-presentation","fullItemName":"Initial presentation"},{"id":"fd10e131-3f32-5228-a05b-5a6267fef1b2","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"eb9fc872-e7a9-5863-bdf8-a59e3bd632f5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"7f20e1da-bbf8-57a8-a08c-b31179f8d6f2","slug":"diagnosing-a-relapse","fullItemName":"Diagnosing a relapse"}]},{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","fullItemName":"Management","slug":"management","subChapters":[{"id":"0191f771-fc85-5664-89d2-67c7d170e292","slug":"general-management","fullItemName":"Scenario: General management"},{"id":"6c75c07e-8dff-5d76-9dd6-24617f774c7b","slug":"managing-a-relapse","fullItemName":"Scenario: Managing a relapse"},{"id":"41a80c0f-66c4-59e9-b83f-74fe33a4ea7e","slug":"managing-complications","fullItemName":"Scenario: Managing complications"}]},{"id":"edace7ac-83b8-5cf1-87da-709d39382122","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"51308a75-1f5a-5ec7-87a2-42bac2d0f697","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"492510e2-a07f-5248-9cf7-ca78c4c5dd7d","slug":"baclofen","fullItemName":"Baclofen"},{"id":"4ce98dc6-eb95-55cd-b840-e2ce178eecbe","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"10cf6767-f716-53c7-abf5-fb44584b2bea","slug":"amitriptyline","fullItemName":"Amitriptyline"}]},{"id":"e3101b52-b59a-5107-b7e1-5927f9b1ac3b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d9a4c686-396a-5209-81c6-42f9e9a35598","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8534fa8f-86c0-5a20-91f4-eb030ff54379","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efebc734-6f42-5782-b6db-8c1dafca9d26","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3991ab27-1fd8-5fe7-b3dd-c9fb7fa1657e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e53280a5-7955-5f7d-86bb-6514173c53af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"eb1acd9f-4671-5653-800c-75002b20feb8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"91ad41f7-47f3-5057-a6de-8a37baf9edbc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7d30fb43-cd66-5aab-af72-8e461bc91727","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"9c7294ad-221d-5c70-b341-2a9fe55289d3","slug":"secondary-care","fullItemName":"Secondary care","depth":3,"htmlHeader":"<!-- begin field bb4026fb-f26b-4397-8e95-a79b00aab957 --><h3>Additional information about what may occur in secondary care</h3><!-- end field bb4026fb-f26b-4397-8e95-a79b00aab957 -->","summary":null,"htmlStringContent":"<!-- begin item 47446c7a-858b-4c22-bd6c-a79b00aab79c --><!-- begin field 9336242c-8f84-4723-b892-a79b00aab957 --><ul><li><strong>A consultant neurologist will normally confirm the diagnosis of multiple sclerosis (MS) based on established up-to-date criteria such as the revised <a href=\"https://www.mstrust.org.uk/a-z/mcdonald-criteria\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"a6449498-a02c-48a6-a1cb-ac2300e4b821\">McDonald criteria</a> after:</strong><ul><li>Confirming that episodes are consistent with an inflammatory process.</li><li>Excluding alternative diagnoses.</li><li>Establishing that lesions have developed at different times and are in different anatomical locations for a diagnosis of relapsing-remitting MS.</li><li>Establishing progressive neurological deterioration over at least 1 year for a diagnosis of primary progressive MS.</li></ul></li><li><strong>If the diagnosis is confirmed, the specialist team will:</strong><ul><li>Consider whether treatment with disease-modifying therapy (DMT) is appropriate — information on DMTs is available from the Association of British Neurologists: revised (2015) <a href=\"https://pn.bmj.com/content/15/4/273\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"f793b923-7fe1-4ab5-aace-ac2300e56071\">guidelines for prescribing disease-modifying treatments in multiple sclerosis</a>.</li><li>Organize multidisciplinary management and follow up of the person, as appropriate to their needs and severity of the disease.</li></ul></li></ul><!-- end field 9336242c-8f84-4723-b892-a79b00aab957 --><!-- end item 47446c7a-858b-4c22-bd6c-a79b00aab79c -->","subChapters":[]},{"id":"417b3f9e-9e4d-5980-925c-e74ebb266364","slug":"basis-for-recommendation-948","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 5c188d2f-d3f9-45aa-89c9-a79b00aa04e8 --><h3>Basis for recommendation</h3><!-- end field 5c188d2f-d3f9-45aa-89c9-a79b00aa04e8 -->","summary":null,"htmlStringContent":"<!-- begin item 9485ca16-9714-4c85-abc1-a79b00aa0358 --><!-- begin field f6d9f7b3-0172-4326-8e95-a79b00aa04e8 --><p>The recommendations on confirmation of diagnosis of multiple sclerosis (MS) are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">BMJ Best Practice, 2020</a>].</p><h4>Referral to a consultant neurologist</h4><ul type=\"disc\"><li>The NICE guideline recommends that people with suspected MS are referred to neurology and that only a consultant neurologist should diagnose MS.</li><ul type=\"circle\"><li>Diagnosis of MS is based on a combination of clinical, imaging, and laboratory findings and should not be diagnosed on the basis of magnetic resonance imaging findings alone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li><li>People who have had an episode of isolated optic neuritis, confirmed by an ophthalmologist, should be referred to a consultant neurologist for further assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li></ul><li>There is increasing evidence that early diagnosis and initiation of disease-modifying treatment may improve prognosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Rae-Grant, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Dobson, 2019b</a>].</li><ul type=\"circle\"><li>Neuroaxonal damage starts early in relapsing-remitting MS and accumulates over time — this is thought to lead to progressive disability later in the condition. Early intervention with disease-modifying drugs has been shown to reduce or delay long-term disability [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Dobson, 2019b</a>].</li></ul></ul><h4>Arranging initial blood tests</h4><ul type=\"disc\"><li>Information on tests to perform on a person suspected of having MS is based on NICE guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li><ul type=\"circle\"><li>The NICE guideline development group used informal consensus to agree a list of tests that they considered important in ruling out the diagnosis of MS before referral to a consultant neurologist, but stated that these tests should not delay urgent referral if that is required on clinical grounds.</li><li class=\"MsoNormal\" style=\"mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; line-height: normal; mso-list: l0 level2 lfo2; tab-stops: list 72.0pt;\">The tests listed are not an exhaustive list and depending on clinical presentation, other tests might be appropriate.</li></ul></ul><!-- end field f6d9f7b3-0172-4326-8e95-a79b00aa04e8 --><!-- end item 9485ca16-9714-4c85-abc1-a79b00aa0358 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}